Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
申请公布号
WO2006104852(A3)
申请公布日期
2007.02.01
申请号
WO2006US10600
申请日期
2006.03.22
申请人
REGENERON PHARMACEUTICALS, INC.;DIX, DANIEL;FRYE, KELLY;KAUTZ, SUSAN
